NSCH becomes Proteonomix
This article was originally published in The Rose Sheet
Executive SummaryBiotech firm National Stem Cell Holdings announces name change to Proteonomix and change of trading symbol from NHGI to PROTD, makes official its focus on proteomics and its movement from strict R&D to commercial product development. In July, the company introduced its new cosmeceutical line featuring "unique natural matrix of proteins called Secreted Matrix and Matrix NC-138" through subsidiary Proteoderm, whose first public display of the skin-care products at recent International Anti-Aging Conference in Washington D.C. met with an "encouraging response." Proteoderm has plans for "an extensive array of specialty skin-care products" formulated with its proprietary proteins derived from non-embryonic stem cells," according to the release. Protenomix believes it now is in a position to raise capital in "very challenging financial environment for product commercialization.
You may also be interested in...
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.